PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2888314-1 1987 The purpose of this study is to investigate the effect of peptide YY (PYY) on pentagastrin-, histamine-, and bethanechol-stimulated gastric acid secretion and the possible mechanisms by which PYY inhibits gastric acid secretion. Pentagastrin 78-90 peptide YY Canis lupus familiaris 58-68 2888314-1 1987 The purpose of this study is to investigate the effect of peptide YY (PYY) on pentagastrin-, histamine-, and bethanechol-stimulated gastric acid secretion and the possible mechanisms by which PYY inhibits gastric acid secretion. Pentagastrin 78-90 peptide YY Canis lupus familiaris 70-73 2888314-1 1987 The purpose of this study is to investigate the effect of peptide YY (PYY) on pentagastrin-, histamine-, and bethanechol-stimulated gastric acid secretion and the possible mechanisms by which PYY inhibits gastric acid secretion. Pentagastrin 78-90 peptide YY Canis lupus familiaris 192-195 2888314-20 1987 Furthermore, PYY inhibit pentagastrin-stimulated gastric acid secretion in the face of atropine, vagotomy, or indomethacin treatment. Pentagastrin 25-37 peptide YY Canis lupus familiaris 13-16 2156661-7 1990 Our data suggest that terbutaline-induced inhibition of pentagastrin-stimulated gastric acid secretion is mediated, at least in part, by the release of PYY and GIP. Pentagastrin 56-68 peptide YY Canis lupus familiaris 152-155 3671783-4 1987 administration of PYY at 200 pmol/kg/h inhibited pentagastrin (1 microgram/kg/h)-stimulated gastric acid output (P less than 0.05). Pentagastrin 49-61 peptide YY Canis lupus familiaris 18-21 3671783-8 1987 The present study demonstrates that PYY can interact with secretin and duodenal acidification in an additive fashion to inhibit pentagastrin-stimulated gastric acid secretion. Pentagastrin 128-140 peptide YY Canis lupus familiaris 36-39 2868024-3 1986 The present study seeks to determine the mechanism by which PYY inhibits acid secretion by examining the effects of PYY on gastric acid stimulated by pentagastrin, histamine, and bethanechol. Pentagastrin 150-162 peptide YY Canis lupus familiaris 60-63 2868024-3 1986 The present study seeks to determine the mechanism by which PYY inhibits acid secretion by examining the effects of PYY on gastric acid stimulated by pentagastrin, histamine, and bethanechol. Pentagastrin 150-162 peptide YY Canis lupus familiaris 116-119 2868024-6 1986 This same dose of PYY maximally inhibited histamine- and pentagastrin-stimulated acid secretion by 28 +/- 7% (P less than 0.05), and 17 +/- 4% (P less than 0.05), respectively. Pentagastrin 57-69 peptide YY Canis lupus familiaris 18-21 1443144-4 1992 Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol.kg-1 x h-1) inhibited pentagastrin (0.5 microgram.kg-1 x h-1)-stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy-D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner. Pentagastrin 110-122 peptide YY Canis lupus familiaris 30-33 1443144-4 1992 Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol.kg-1 x h-1) inhibited pentagastrin (0.5 microgram.kg-1 x h-1)-stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy-D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner. Pentagastrin 110-122 peptide YY Canis lupus familiaris 42-45 1443144-4 1992 Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol.kg-1 x h-1) inhibited pentagastrin (0.5 microgram.kg-1 x h-1)-stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy-D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner. Pentagastrin 110-122 peptide YY Canis lupus familiaris 42-45